Vanda Pharmaceuticals Inc
VNDA
查看详细走势图
6.830USD
-0.200-2.85%
交易中 （美东）报价延迟15分钟
403.62M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.85%
5天
+3.02%
1月
+42.29%
6月
+51.44%
今年开始到现在
+42.59%
1年
+42.89%
查看详细走势图
TradingKey Vanda Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-22操作建议
Vanda Pharmaceuticals Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名16/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.75。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Vanda Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
买入
评级
11.750
目标均价
+91.37%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Vanda Pharmaceuticals Inc亮点
亮点风险
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
业绩转亏
公司业绩转亏，最新年度亏损美元
估值合理
公司最新PE估值-4.91，处于3年历史合理位
机构减仓
最新机构持股46.45M股，环比减少17.70%
默里·斯塔尔持仓
明星投资者默里·斯塔尔持仓，最新持仓市值25.91K
Vanda Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Vanda Pharmaceuticals Inc简介
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
公司代码VNDA
公司Vanda Pharmaceuticals Inc
CEOPolymeropoulos (Mihael Hristos)
网址https://www.vandapharma.com/
常见问题
Vanda Pharmaceuticals Inc(VNDA)的当前股价是多少？
Vanda Pharmaceuticals Inc(VNDA)的当前股价是 6.830。
Vanda Pharmaceuticals Inc的股票代码是什么？
Vanda Pharmaceuticals Inc的股票代码是VNDA。
Vanda Pharmaceuticals Inc股票的52周最高点是多少？
Vanda Pharmaceuticals Inc股票的52周最高点是7.050。
Vanda Pharmaceuticals Inc股票的52周最低点是多少？
Vanda Pharmaceuticals Inc股票的52周最低点是3.809。
Vanda Pharmaceuticals Inc的市值是多少？
Vanda Pharmaceuticals Inc的市值是403.62M。
Vanda Pharmaceuticals Inc的净利润是多少？
Vanda Pharmaceuticals Inc的净利润为-18.90M。
现在Vanda Pharmaceuticals Inc(VNDA)的股票是买入、持有还是卖出？
根据分析师评级，Vanda Pharmaceuticals Inc(VNDA)的总体评级为买入，目标价格为11.750。
Vanda Pharmaceuticals Inc(VNDA)股票的每股收益（EPS TTM）是多少
Vanda Pharmaceuticals Inc(VNDA)股票的每股收益（EPS TTM）是-1.431。
相关品种
